Please assess the completion status of the following clinical trial:

Trial Title: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 11.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Metastatic melanoma with evaluable disease.~* Greater than or equal to 18 years of age and less than or equal to age 66.~* Willing to sign a durable power of attorney~* Able to understand and sign the Informed Consent Document~* Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1~* Life expectancy of greater than three months~* Patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after the cells are no longer detected in the blood.~* Serology:~  * Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities.)~ * Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by reverse transcription polymerase chain reaction (RT-PCR) and be hepatitis C virus ribonucleic acid (HCV RNA) negative.~ * Women of child-bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the preparative chemotherapy on the fetus.~* Hematology:~  * Absolute neutrophil count greater than 1000/mm\^3 without the support of filgrastim.~ * White blood cell (WBC) (\> 3000/mm\^3).~ * Platelet count greater than 100,000/mm\^3.~ * Hemoglobin greater than 8.0 g/dl.~* Chemistry:~  * Serum alanine transaminase (ALT)/aspartate transaminase (AST) less or equal to 2.5 times the upper limit of normal.~ * Serum creatinine less than or equal to 1.6 mg/dl.~ * Total bilirubin less than or equal to 1.5 mg/dl, except in patients with Gilberts Syndrome who must have a total bilirubin less than 3.0 mg/dl.~* More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo).~EXCLUSION CRITERIA:~* Previous treatment with interleukin-12 (IL-12).~* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.~* Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.~* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).~* Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities).~* Concurrent systemic steroid therapy.~* History of severe immediate hypersensitivity reaction to any of the agents used in this study.~* In patients \> 60 years old and/or history of coronary revasularization or ischemic symptoms, documented left ventricular ejection fraction (LVEF) of less than or equal to 45%.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 - CD8 + TIL expressing IL-12 1x10^6 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of interleukin-12 (IL-12) gene-transduced tumor infiltrating lymphocytes (TIL).
- Group 2 - CD8 + TIL expressing IL-12 3x10^6 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
- Group 3 - CD8 + TIL expressing IL-12 1x10^7 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
- Group 4- CD8+TIL expressing IL-12 3x10^7 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
- Group 5 - Bulk TIL expressing IL-12 1x10^7 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
- Group 6 - Bulk TIL expressing IL-12 3x10^7 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
- Group 7- Bulk TIL expressing IL-12 1x10^8 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
- Group 8 - Bulk TIL expressing IL-12 3x10^8 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
- Group 9 - Bulk TIL expressing IL-12 1x10^9 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
- Group 10- Bulk TIL expressing IL12 3x10^9 (Type: EXPERIMENTAL): Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
- Group 11 - Bulk TIL expressing MTD 1x10^9 (Phase 2) (Type: EXPERIMENTAL): Maximum tolerated dose (MTD). Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues